Astria Therapeutics Aktie Logo
US04635X1028
A3C2EY
ATXS

Astria Therapeutics Aktie

Prognose

Analytikernes gennemsnitlige kursmål er 17,68 € (+66,17 %). Medianen er 18,23 € (+71,33 %).

Køb
  3
Behold
  5
Sælg
  0

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

  • Astria Therapeutics reports strong phase‑1b/2 data for HAE drug Navenibart

    The ALPHA‑STAR study of 29 patients showed clear efficacy for Navenibart and a favorable safety profile: median reductions in HAE attack rate of 84–92% over six months and attack‑free rates of 62% and 67% in expanded cohorts. No serious adverse events or study discontinuations were reported; four non‑serious, treatment‑related events resolved quickly. Astria Therapeutics has initiated the phase‑3 ALPHA‑ORBIT study on schedule, with initial results expected in early 2027, and is conducting an open‑label long‑term extension. » Mere på de.investing.com


  • Astria Therapeutics starts phase‑3 long‑term study ORBIT‑EXPANSE for HAE therapy Navenibart

    Astria Therapeutics has started the phase‑3 long‑term study ORBIT‑EXPANSE for Navenibart to prevent hereditary angioedema; participants from the approval‑relevant ALPHA‑ORBIT study can transition. The study includes a fixed dosing phase of at least six months followed by a flexible phase in which patients can receive quarterly or semiannual subcutaneous doses. In parallel, the company is developing the OX40 antibody STAR‑0310 with positive phase‑1a results, and H.C. Wainwright reaffirmed a “Buy” rating and raised the price target to $20.00. » Mere på de.investing.com


  • Astria reports positive Phase‑1a results for long‑acting OX40 antibody STAR‑0310

    Astria Therapeutics reports that STAR‑0310 showed a half‑life of up to 68 days in a Phase‑1a study in healthy volunteers, dose‑proportional increases in concentrations and sustained ex‑vivo cytokine inhibition for 16–20 weeks. The drug was well tolerated at all dose levels; there were no serious treatment‑related events and only seven mild, self‑resolving adverse events. Astria plans an update to its development plans and will present the data at the EAADV congress; analyst targets range from $16 to $49. At a share price of $7.27 the balance sheet shows more cash than debt, but the company remains unprofitable. » Mere på de.investing.com

Virksomhedstal

I det seneste kvartal havde Astria Therapeutics Aktie en omsætning på 601,6 t € og et nettoresultat på -26,96 mio. €

(EUR) september 2025
YoY
Omsætning 601,6 t -
Bruttofortjeneste 601,6 t -
Nettoresultat -26,96 mio. -
EBITDA -26,96 mio. -

Fundamentale data

Nøgletal Værdi
Markedsværdi
654,47 mio. €
Antal aktier
57,08 mio.
Højeste/laveste i 52 uger
12,11 € - 3,24 €
Udbytte Nej
Beta
0,02
P/E (PE Ratio)
-11,23
PEG (PEG Ratio)
1,37
K/I (PB Ratio)
3,13
P/S (PS Ratio)
1.017,18

Virksomhedsprofil

Astria Therapeutics, Inc., et biofarmaceutisk selskab, fokuserer på opdagelse, udvikling og kommercialisering af lægemidler mod sjældne og nicheprægede allergiske og immunologiske sygdomme i USA. Dens vigtigste produktkandidat er STAR-0215, en monoklonal antistofhæmmer af plasma-kallikrein, som er i den prækliniske udviklingsfase til behandling af hereditært angioødem. Selskabet var tidligere kendt som Catabasis Pharmaceuticals, Inc. og skiftede navn til Astria Therapeutics, Inc. i september 2021. Astria Therapeutics, Inc. blev stiftet i 2008 og har hovedsæde i Boston, Massachusetts.

Navn
Astria Therapeutics Aktie
CEO
Jill C. Milne
Hjemsted Boston, ma
USA
Websted
Sektor
Materialer
Branche
Kemikalier
Børsnotering
25.06.2015
Medarbejdere 78

Tickersymboler

Børs Symbol
NASDAQ
ATXS
🍪

Parqet  bruger cookies. Læs mere